 |
|
 |
|
|
|
 What is RSS?
New SSRI inquiry to consider patient experiences
The Government has conceded to intense pressure to give patients input into a new inquiry on the safety of SSRI antidepressants...(more)
Xeloda recommended for breast and colorectal cancer
Roche new mart pillXeloda has been recommended by NICE for the treatment of advanced breast and bowel cancer...(more)
Parallel imports save NHS millions, say health economists
Parallel trade in medicines between EU countries saved patients and national health systems £635 million in 2002, according to a new study...(more)
BMJ puts industry relations under spotlight
Patients would benefit from less involvement between pharmaceutical companies and the medical profession, according to new research...(more)
BMA presses ahead with make-or-break contract vote
Doctors in the UK are to vote on the long-awaited GP contract next week, despite calls by GP representatives to delay the ballot by six months...(more)
Investors win battle of JP's golden parachute
GlaxoSmithKline has signalled a re-think over Chief Executive Jean-Pierre Garnier's $35.7 million (£22m) 'golden parachute' pay deal after a shareholder revolt of unprecedented scale...(more)
GSK pipeline fuelled by purchases
GlaxoSmithKline leads the industry in licensing in new drugs, buying the rights to nearly twice as many products as its rivals, according to new research...(more)
Pele keeps playing for Pfizer
Pele has signed up with Pfizer to continue his work on raising awareness of erectile dysfunction for the pharma company...(more)
Data boosts Seroquel manic depression indication
AstraZeneca's schizophrenia drug Seroquel could provide a further sales boost for the company after new data indicated its efficacy in treating bipolar disorder...(more)
Humira one step closer to European market
Abbott Labs' human monoclonal antibody Humira has received a positive opinion from the EMEA for the treatment of rheumatoid arthritis, the first such drug to do so in Europe...(more)
Omeprazole could be first in wave of blockbuster switches
Omeprazole, the blockbuster ulcer drug discovered by AstraZeneca, could soon be dispensed by pharmacists without a prescription, pending final approval by regulators...(more)
Milburn says 'not yet' to foundation PCTs
Mental health and primary care trusts could eventually take on foundation status, according to Health Secretary Alan Milburn...(more)
MCA playing ussian roulettewith lives, says charity
Mental health charity MIND has criticised the way the Medicines Control Agency handles drug regulation, saying "it is playing Russian roulette with people lives"...(more)
Delayed Celebrex successor approved in Europe
Pfizer's follow up to its multi-billion dollar painkiller Celebrex has been approved for marketing across the European Union following a lengthy delay...(more)
Crunch time for Crestor
AstraZeneca is bracing itself for what could be a make-or-break FDA ruling on its 'superstatin' blockbuster candidate Crestor...(more)
US Court ruling could be $7bn blow to industry
A ruling by the US Supreme Court could clear the way for US states to enforce hugely increased prescription price discounts costing pharmaceutical companies up to $7 billion...(more)
Lilly rapped for Cialis' premature marketing
Eli Lilly has been publicly reprimanded for bringing the pharmaceutical industry into disrepute after promoting its erectile dysfunction treatment Cialis months ahead of receiving marketing authorisation...(more)
CAT hopeful despite growing losses
UK biotech company Cambridge Antibody Technology says it remains on target to reach profitability by 2008 despite a doubling of its operating losses in the first half of this year...(more)
Cancer care threatened by lack of funds
One of the UK leading cancer hospitals will be forced to restrict access to treatment because of a shortage of funds...(more)
Hassan hits the ground running on Schering-Plough re-organisation
Fred Hassan has announced a major re-organisation of Schering-Plough pharmaceutical operations just 17 days after taking on the job of turning around the ailing business...(more)
Trial failure forces Xenova cutbacks
Xenova has halted phase III clinical trials of its lead product after an independent safety committee confirmed safety fears about the drug...(more)
Six-month delay could be fatal for GP contract
The crisis surrounding the proposed new GP contract has deepened after doctors refused to be tampededinto accepting a new contract, which many say contain isastrous flaws...(more)
Roche launches first proactive patient helpline
Roche and health call-centre specialists International SOS have launched the UK first ever helpline to proactively support patients to keep taking their prescription...(more)
UK research centre falls victim to Pfizer merger
A leading UK drug discovery centre is one of a number of global sites to close following Pfizer's recently completed $53 billion acquisition of Pharmacia...(more)
Primary care leaders dismayed by foundation trust sideshow
Primary care leaders have expressed their fears that foundation trusts could undermine recent gains by returning the NHS to a secondary care-led system...(more)
PowderJect takeover edges closer
UK vaccines specialist PowderJect has confirmed it is in advanced discussions about a new takeover bid for the company...(more)
Private sector invited to run NHS surgery centres
Private sector companies have been invited to run the latest wave of new diagnostic treatment centres (DTC) to help cut waiting times for routine surgery...(more)
Import blow to AstraZeneca
The European Court has ruled that parallel imported versions of Losec can be sold in Sweden despite AstraZeneca having withdrawn its marketing authorisation for the drug...(more)
Rebels fail to halt foundation trust plans
The Government has won a crucial House of Commons vote in favour of its plans to allow top-performing hospitals to become foundation trusts...(more)
Generics begin assault on Zocor
Merck Zocor, one of the biggest-selling drugs of all time, is set to lose up to 90% of its UK sales overnight following the introduction of generic competition...(more)
UK pharma sends aid to Iraq
Pharmaceutical companies in the UK have responded to the humanitarian crisis in post-war Iraq by sending over 60 tonnes of emergency medicines in the first despatch of vital supplies...(more)
GSK to remove Seroxat 'not addictive' claim
GlaxoSmithKline is to drop claims on patient information leaflets that its antidepressant Seroxat is not addictive...(more)
FDA clears Iressa of safety concerns
AstraZeneca lung cancer drug Iressa has gained US approval after an extended review found the drug to be safe, despite cases of serious and sometimes fatal side-effects...(more)
Risk-sharing agreement failing MS patients
Thousands of patients have yet to benefit from an innovative scheme to increase access to multiple sclerosis drugs, more than a year after it was introduced...(more)
Vernalis seeks funding and takeover offers
UK biotechnology company Vernalis is hoping a new £14 million share offer will keep its head above water following the recent collapse in its share price...(more)
GSK prospers despite generic competition
GlaxoSmithKline has posted 11% growth in the first quarter of 2003 despite generic competition for its blockbuster antibiotic Augmentin...(more)
Blair and Milburn braced for foundation trust backlash
The Government's controversial plans to introduce foundation hospitals are on a knife-edge ahead of a Commons vote on the reform next week...(more)
PowderJect rises on takeover bid
Shares in UK vaccines specialist PowderJect rose nearly 8% after it confirmed an unnamed company had made a buyout offer...(more)
AZ promise despite Losec drop
Generic competition to Losec limited AstraZeneca sales growth in the first quarter although strong growth of other products has indicated underlying promise...(more)
GlaxoSmithKline slashes AIDS drug prices
GlaxoSmithKline has cut prices of its HIV/AIDS drugs for developing countries by nearly half following intense pressure from campaigners and investors...(more)
GPs 'in favour' of charging patients
Nearly three in five doctors would like to be able to charge their patients for home visits, according to a new survey...(more)
International performance keeps BMS afloat
International sales of several key drugs helped Bristol-Myers Squibb to minimise the effects of continued US generic competition in the first quarter of 2003...(more)
|
|
|
|
|
|
|
|
|
|
|
